Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Accumulated Expenses (2019 - 2025)

Revolution Medicines has reported Other Accumulated Expenses over the past 7 years, most recently at $7.9 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $7.9 million for Q4 2025, up 1247.86% from a year ago — trailing twelve months through Dec 2025 was $7.9 million (up 1247.86% YoY), and the annual figure for FY2025 was $7.9 million, up 1247.86%.
  • Other Accumulated Expenses for Q4 2025 was $7.9 million at Revolution Medicines, down from $8.2 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for RVMD hit a ceiling of $8.2 million in Q3 2025 and a floor of $99000.0 in Q2 2021.
  • Median Other Accumulated Expenses over the past 5 years was $496500.0 (2022), compared with a mean of $1.4 million.
  • Biggest five-year swings in Other Accumulated Expenses: plummeted 85.64% in 2021 and later skyrocketed 1247.86% in 2025.
  • Revolution Medicines' Other Accumulated Expenses stood at $311000.0 in 2021, then soared by 62.38% to $505000.0 in 2022, then soared by 671.49% to $3.9 million in 2023, then crashed by 85.04% to $583000.0 in 2024, then skyrocketed by 1247.86% to $7.9 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $7.9 million (Q4 2025), $8.2 million (Q3 2025), and $462000.0 (Q2 2025) per Business Quant data.